Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Cut to $20.00 by Analysts at Cantor Fitzgerald

Artiva Biotherapeutics (NASDAQ:ARTV) had its target price cut by investment analysts at Cantor Fitzgerald from $23.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 421.51% from the company’s previous close.

A number of other equities research analysts also recently issued reports on ARTV. Wedbush reissued an “outperform” rating and set a $18.00 price objective on shares of Artiva Biotherapeutics in a research report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a report on Tuesday. Finally, HC Wainwright assumed coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Stock Performance

Shares of ARTV traded down $0.08 during trading hours on Tuesday, hitting $3.84. The stock had a trading volume of 23,414 shares, compared to its average volume of 113,040. Artiva Biotherapeutics has a 12 month low of $3.37 and a 12 month high of $17.31. The stock has a fifty day moving average price of $4.97 and a 200 day moving average price of $9.43.

Hedge Funds Weigh In On Artiva Biotherapeutics

Several institutional investors have recently bought and sold shares of ARTV. State Street Corp bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth about $1,337,000. Geode Capital Management LLC purchased a new position in Artiva Biotherapeutics in the third quarter worth about $4,774,000. Barclays PLC bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $304,000. BNP Paribas Financial Markets bought a new stake in Artiva Biotherapeutics during the third quarter worth approximately $42,000. Finally, JPMorgan Chase & Co. purchased a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $166,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.